



RPG LIFE SCIENCES LIMITED
Unit No. 208-213, B Wing,
Bezzola Complex,
Sion-Trombay Road, Chembur,
Mumbai 400071, India
Tel: +91-22-25292152-55
Fax: +91-22-25297423

January 25, 2021

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Unaudited Financial Results for the quarter and nine months ended December 31, 2020

Pursuant to Regulation 33 Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Unaudited Financial Results for the quarter and nine months ended December 31, 2020 which were approved by the Board of Directors of the Company, at its meeting held on January 25, 2021 along with Limited Review Report issued by the Statutory Auditors of the Company.

The meeting commenced at 03:00 p.m. and concluded at 05:30 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

Rajesh Shirambekar
Head – Legal & Company Secretary



Encl: as above

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai - 400 063

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited review report on unaudited quarterly and year-to-date financial results of RPG Life Sciences Limited under regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To the Board of Directors of RPG Life Sciences Limited

1. We have reviewed the accompanying Statement of unaudited financial results of RPG Life Sciences Limited ('the Company') for the quarter ended 31 December 2020 and year to date results for the period from 1 April 2020 to 31 December 2020 ('the Statement').
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP
Chartered Accountants

Firm's Registration No: 101248W/W- 100022



Himanshu Chapsey
Partner

Membership No: 105731

UDIN: 21105731AAAACI3879

Place: Mumbai
Date: 25 January 2021

**STATEMENT OF UNAUDITED FINANCIAL RESULTS
 FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020**

(Rs. in Lakhs)

Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	31-03-2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	10,760	9,713	9,437	29,638	28,690	37,557
2 Other Income	12	4	4	61	35	73
3 Total Income	10,772	9,717	9,441	29,699	28,725	37,630
4 Expenses						
(a) Cost of Materials Consumed	2,175	2,680	2,273	6,769	5,696	7,513
(b) Purchases of Stock-in Trade	1,517	809	1,849	3,831	4,934	5,861
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	131	(392)	(932)	(753)	(906)	(598)
(d) Employee Benefits Expense	2,437	2,441	2,281	7,186	6,841	9,097
(e) Finance Costs	16	23	36	70	145	175
(f) Depreciation and Amortisation Expense	419	420	416	1,255	1,224	1,636
(g) Other Expenses	2,370	2,263	2,477	6,878	7,460	9,769
Total Expenses	9,065	8,244	8,400	25,236	25,394	33,453
5 Profit before exceptional items and tax	1,707	1,473	1,041	4,463	3,331	4,177
6 Exceptional Items Gain/(Loss) (See Note 3)	-	-	-	-	-	(532)
7 Profit before tax	1,707	1,473	1,041	4,463	3,331	3,645
8 Income tax expenses						
a. Current Tax	536	473	327	1,420	948	1,010
b. Deferred Tax	(116)	(115)	(77)	(265)	(220)	(266)
9 Profit for the period	1,287	1,115	791	3,308	2,603	2,901
10 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	(6)	(6)	(10)	(18)	(30)	(24)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	2	1	2	5	8	7
Other Comprehensive Income Net of Tax	(4)	(5)	(8)	(13)	(22)	(17)
11 Total Comprehensive Income for the period	1,283	1,110	783	3,295	2,581	2,884
12 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
13 Other Equity						16,334
14 Earnings per Share (of Rs.8/- each) (not annualised for the quarter):						
(a) Basic	7.78	6.74	4.78	20.00	15.74	17.54
(b) Diluted	7.78	6.74	4.78	20.00	15.74	17.54



RPG LIFE SCIENCES LIMITED

Regd. Off.: RPG House
463, Dr. Annie Besant Road
Worli, Mumbai 400030, India
Tel: +91-22-24981650 / 66606375
Fax: +91-22-24970127
Email: info@rpglifesciences.com
www.rpglifesciences.com
CIN : L24232MH2007PLC169354

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 25, 2021.
2. The Company operates in only one reportable business segment i.e., Pharmaceuticals.
3. Exceptional items for the year ended March 31, 2020 relates to write off of an intangible asset under development. The Company does not expect any future economic benefits to flow to the Company hence the cost incurred till date have been charged off during the quarter ended March 31, 2020.
4. The Company has considered internal and external information while finalizing various estimates and recoverability of assets in relation to its financial statement captions upto the date of approval of the financial results by the Board of Directors. The impact of Covid-19 may be different from what is estimated as at such date of approval of the financial results and the Company will continue to monitor any material changes to future economic conditions.



For RPG Life Sciences Limited

Yugal Sikri
Managing Director
Mumbai, January 25, 2021